Drug General Information
Drug ID
D0ZV0R
Former ID
DIB001971
Drug Name
F-200
Synonyms
Eos-200-F; Anti-alpha-5/beta-1 integrin Ab Fragment, PDL; Anti-alpha-5/beta-1 integrin Fab, PDL; Anti-alpha-5/beta-1 integrin Fab, Protein Design Labs
Drug Type
Small molecular drug
Indication Ocular disease [ICD10:H00-H59] Terminated [547693]
Company
Eos Biotechnology Inc
Structure
Download
2D MOL

3D MOL

Formula
C22H32Cl2N2
Canonical SMILES
CC(CC1=CC=CC=C1)N2CCN(CC2)C(C)CC3=CC=CC=C3.Cl.Cl
InChI
1S/C22H30N2.2ClH/c1-19(17-21-9-5-3-6-10-21)23-13-15-24(16-14-23)20(2)18-22-11-7-4-8-12-22;;/h3-12,19-20H,13-18H2,1-2H3;2*1H
InChIKey
MQZLPLLJULLBQC-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Integrin alpha-5/beta-1 Target Info Inhibitor [550929]
KEGG Pathway Phagosome
PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Hematopoietic cell lineage
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Shigellosis
Pertussis
Proteoglycans in cancer
MicroRNAs in cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
WikiPathways Focal Adhesion
Extracellular matrix organization
Elastic fibre formation
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Cell surface interactions at the vascular wall
References
Ref 547693Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018439)
Ref 550929US patent application no. 8,541,413, Sustained release eye drop formulations.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.